JPS6260106B2 - - Google Patents
Info
- Publication number
- JPS6260106B2 JPS6260106B2 JP55035217A JP3521780A JPS6260106B2 JP S6260106 B2 JPS6260106 B2 JP S6260106B2 JP 55035217 A JP55035217 A JP 55035217A JP 3521780 A JP3521780 A JP 3521780A JP S6260106 B2 JPS6260106 B2 JP S6260106B2
- Authority
- JP
- Japan
- Prior art keywords
- suppressor
- cells
- cell
- carrier
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 10
- 210000001124 body fluid Anatomy 0.000 claims description 10
- 239000010839 body fluid Substances 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 10
- 230000001506 immunosuppresive effect Effects 0.000 claims description 10
- 230000001715 anti-suppressor Effects 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 6
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 6
- 108010074605 gamma-Globulins Proteins 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 4
- 229920001282 polysaccharide Polymers 0.000 claims description 4
- 239000005017 polysaccharide Substances 0.000 claims description 4
- 229920003002 synthetic resin Polymers 0.000 claims description 4
- 239000000057 synthetic resin Substances 0.000 claims description 4
- 239000002657 fibrous material Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- 210000005008 immunosuppressive cell Anatomy 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- -1 polyoxymethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
発明の背景
技術分野
本発明は、体液中の免疫抑制機能を有する細胞
の除去装置に関する。
先行技術及びその問題点
免疫抑制性細胞の一種であるサプレツサーT細
胞は、健康人でも血液中に低比率で存在し、自己
抗体産生による自己抗原との反応を未然に阻止し
て、生体の維持に寄与している。しかし、癌患
者、免疫不全症患者など免疫系が異常となつた疾
患患者では、このサプレツサーT細胞が異常に増
強されて、ヘルパーT細胞、B細胞など抗体産生
を促進させる細胞の機能を抑制する。このためこ
れらの患者は、液性免疫能のみならず細胞性免疫
能まで低下し、この結果非自己あるいは修飾され
た自己抗原に対して生体防御反応が働かず、疾患
の進行を促進して、その症状を悪化させることと
なる。
従来は、サプレツサーT細胞の増強を阻止する
ために、化学療法、放射線療法、外科療法などが
なされているが、これら療法は、他の細胞をも損
傷するためその目的を十分には達成できない。
免疫抑制性細胞を血液から分離してこれを取除
くことも考えられるが、従来の技術では他の有用
な細胞までも除去してしまう。
発明の目的
本発明の目的は、免疫抑制性細胞であるサプレ
ツサーT細胞を選択的に除去する方法およびその
装置を提供するものである。
上記目的を達成するものは、サプレツサーT細
胞を含む体液を、抗サプレツサーT細胞抗体を固
定した担体に接触させ、該体液内のサプレツサー
T細胞を該担体に補足させて除去するサプレツサ
ーT細胞除去方法である。
また、前記抗サプレツサーT細胞抗体は、免疫
抑制能をもつ抗原に対して免疫反応性を有する非
動化した血清を赤血球で吸収操作した後この血清
から1/3硫安飽和法にて分離したγ−グロブリン
分画のものであることが好ましい。
また、上記目的を達成するものは、サプレツサ
ーT細胞を含む体液が流通可能な容器と、該容器
内に収容された抗サプレツサーT細胞抗体を固定
した担体とからなるサプレツサーT細胞除去装置
である。
また本発明は担体が繊維状物、管状物、顆粒状
物、球状物又は膜状物であり、その材質が活性
炭、多糖体、蛋白質又は合成樹脂である。
更にまた抗体は、免疫抑制能をもつ抗原に対し
て免疫反応性を有する非働化した血清を赤血球で
吸収操作した後、この血清から1/3硫安飽和法に
て抽出したγ−グロブリン分画のものである。
発明の具体的説明
第1図は体液中免疫抑制性細胞の除去装置を示
し、この除去装置は容器1内に担体2を収容して
いる。この容器1は、両端に血液流入口3及び血
液流出口4を形成し、出入口部にそれぞれフイル
ター5,5を設けている。これらフイルター5,
5は、担体2が容器1外に流出するのを防ぐもの
である。
この担体2は、免疫抑制性細胞の細胞膜抗原す
なわち細胞膜を抗原として特異的に反応する抗体
を固体化したもので、繊維状物、管状物、顆粒状
物又は球状物で形成されている。この担体2は、
ここを通る血液等の体液が抗体と効率よく接触す
る程度充填するのが好ましい。
これらの形状を有する担体2の材質としては、
活性炭、多糖体、蛋白質、合成樹脂などが適当
で、多糖体としてセルロース、アガロース、フイ
ブリン、コラーゲンなどが挙げられる。又合成樹
脂としてポリスチレン、ポリ塩化ビニール、ポリ
ビニルアルコール、ポリビニルピロリドン、ポリ
カーボネイト、ナイロン、シリコーン、ポリオキ
シメチレンなどが挙げられる。なおこれらの材質
は担体2の全体に限らず、抗体を付着する表面に
のみ形成してもよい。
担体2に固定される抗体は、除去すべき免疫抑
制性細胞がサプレツサーT細胞のときは、抗サプ
レツサーT細胞抗体である。この抗サプレツサー
T細胞抗体は例えば免疫抑制能が確認された細胞
を抗原として所定の動物に免疫し、免疫後の血液
から血清を分離して非働化し、更に赤血球で吸収
操作を行つた血清から1/3硫安飽和法で抽出した
γ−グロブリン分画のものである。この抗体を担
体に固定化するには、例えばグルタールアルデヒ
ドを用いた公知方法を用いておこなう。
しかして上記担体2を収容した容器1は、第2
図に示すように血液流入口3をドリツプチヤンバ
ー6を介して人体7又は血液保存器に接続し、血
液流出口4をドリツプチヤンバー8を介して人体
7又は血液保存器に接続している。なお図示して
いないが、この装置には血液の凝固を防止するた
めにヘパリンなどの抗凝固剤を血液中に供給する
機構が設けられている。
発明の具体的作用及び効果
このように構成された体液中免疫抑制性細胞の
除去装置は、血液ポンプ9の作動により血液が容
器1を通つて体内に返送される。容器1内では、
担体2に所定の抗体が固定化されているため、こ
れが免疫抑制性細胞の細胞膜抗原に特異的に反応
して、この細胞を選択的に補捉する。この場合免
疫抑制性細胞以外の細胞はこの抗体で補捉され
ず、体内に戻される。また担体2に抗体を固定化
して免疫抑制性細胞を除去するので、流路系の閉
塞や処理能の低下などの操作上の問題はなんら発
生しない。
以上の如き本発明効果は、以下に示す実験によ
つて確認された。
まずこの実験で抗原とするサプレツサーT細胞
は次のようにして得た。
人間の肘静脈から血液200mlを採血し、フイコ
ールーコンレイ比重液に重層し、2000γpmで20
分間遠心分離した後、中間層のリンパ球層を分離
してこれを生理食塩水で2×106ケ/ml浮遊液と
する。この浮遊液を2%ノイラミニダーゼ処理羊
赤血球と混和して400×gで5分間遠心分離し、
これを4℃で1時間静置する。ここでリンパ球を
静かに浮遊させて、再度フイコールーコンレイ比
重液にかけ、2000γpmで20分間遠心分離する。
分離されたロゼツト形成細胞を0.83%塩化アンモ
ニウム溶液で羊赤血球を溶血させた後、生理食塩
水で洗浄(1000γpm、10分間、3回)する。こ
の操作で得られたT細胞を2×106ケ/mlになる
ように生理食塩水を加えて調製する。
次にこれに1%ウサギ抗−ヒトIgG−抗体感作
ニワトリ赤血球を等量混和し、4℃で24時間静置
する。これをフイコールーコンレイ比重液に重層
し、2000γpmで10分間遠心分離して沈殿したロ
ゼツト形成細胞を取出し、次いで0.83%塩化アン
モニウム液でにわとり赤血球を溶血させて、生理
食塩水で洗浄(1000γpm、10分間、3回)す
る。
このような操作で得られたサプレツサーT細胞
の免疫抑制能を調べるために、次のような測定を
おこなつた。
別の健常人から得たリンパ球をフイコールーコ
ンレイ比重遠沈法により、B細胞、T細胞に分離
し、各々の細胞数を2×105ケ/ml、8×105ケ/
mlになるように20%FCS(牛胎児血清)加
RPMI1640−HEPESで調製して対照細胞群とす
る。また分離したT細胞を健常ヒトリンパ球に加
えるときは、B細胞2×105ケ/ml、T細胞2×
105ケ/ml、前記分離したT細胞8×105ケ/mlに
なるように前記培地で調製して、被験細胞群とす
る。対照細胞群、被験細胞群各1mlにPWM(ポ
ークウイードマイトジエン)10μgを添加して、
5%CO2インキユベータ中で37℃で7日間培養す
る。これら対照細胞群、被験細胞群にウサギ抗ヒ
トIg(IgG+IgA+IgM)血清を用いて螢光染色
し、MEM培地で洗浄(1000γpm、5分間、3
回)したのち螢光顕微鏡下で500ケ以上の細胞を
観察し、細胞質内に特異螢光を有する細胞を陽性
としてかぞえ、Ig保有細胞出現率から免疫抑制能
をみた。その結果、対照細胞群では抗体産生細胞
(Ig保有細胞)が6%であるのに対し、被験細胞
群では1.5%と低く、前記分離したT細胞に免疫
抑制能があることが示された。
一方サプレツサーT細胞の抗体は次のようにし
て得た。
免疫抑制能が確認されたリンパ球1×107ケを
抗原として、うさぎに10日間隔で2回免疫した。
最終免疫から7日後全採血し、分離した血清を56
℃で30分間処理して非働化した。これを等量のヒ
トAB型赤血球で37℃、1時間吸収操作をしたの
ち、同様にヒトB細胞でも吸収操作を行つた。こ
のうさぎ抗−ヒトサプレツサーT細胞血清を硫酸
アンモニウムを用いた1/3飽和法にてγ−グロブ
リン分画を得、これをウサギ抗−ヒトサプレツサ
ーT細胞抗体(以下抗体と略す)とした。
次にこの抗体を検定すべく、次の細胞障害性試
験を行つた。
前述したサプレツサーT細胞及び非サプレツサ
ーT細胞をそれぞれ2500ケ/mm3に調製し、マイ
クロテストプレート(#3034、フアルコン、商品
名)にマイクロシリンジで1μ加えた。
次に前記抗体を1μ加え、22℃で45分間培養
する。そのあとウサギ補体5μを加えて、22℃
で90分間培養する。これにエオジン2μを加
え、更にホルマリン(PH7.0)を加えて染色固定
する。そして顕微鏡下で生細胞、死細胞をカウン
トし、死細胞率を算定した結果、サプレツサーT
細胞群は死細胞が95%であるのに対し、非サプレ
ツサーT細胞がは死細胞が5%であつた。以上の
結果からこの抗体がサプレツサーT細胞に特異的
に反応して死滅させることが確認された。またこ
の抗体の細胞毒性を調べるべく、マイクロテスト
プレートを用いたウサギ抗−ヒトサプレツサーT
細胞抗体によるヒトリンパ球細胞障害性試験を行
なつた。その結果第1表に示すようにこの抗体は
2500倍希釈まで細胞毒性を示し、力価の高いこと
が認められた。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a device for removing cells with immunosuppressive functions from body fluids. Prior art and its problems Suppressor T cells, a type of immunosuppressive cell, exist in the blood at a low rate even in healthy people, and prevent reactions with self-antigens caused by autoantibody production to maintain the body's life. contributes to However, in patients with diseases where the immune system is abnormal, such as cancer patients or immunodeficiency patients, these suppressor T cells are abnormally enhanced and suppress the functions of cells that promote antibody production, such as helper T cells and B cells. . For this reason, these patients have a decline in not only humoral immunity but also cellular immunity, and as a result, the body's defenses against non-self or modified self-antigens do not work, accelerating the progression of the disease. This will worsen the symptoms. Conventionally, chemotherapy, radiation therapy, surgical therapy, and the like have been used to prevent the enhancement of suppressor T cells, but these treatments also damage other cells, so they cannot fully achieve their purpose. Although it is possible to remove immunosuppressive cells by separating them from the blood, conventional techniques also remove other useful cells. OBJECTS OF THE INVENTION An object of the present invention is to provide a method and device for selectively removing suppressor T cells, which are immunosuppressive cells. A method for removing suppressor T cells that achieves the above objective involves bringing a body fluid containing suppressor T cells into contact with a carrier on which an anti-suppressor T cell antibody is immobilized, and allowing the carrier to capture and remove the suppressor T cells in the body fluid. It is. In addition, the anti-suppressor T cell antibody is obtained by absorbing immobilized serum that is immunoreactive against antigens with immunosuppressive ability with red blood cells, and then separating it from this serum by a 1/3 ammonium sulfate saturation method. - Preferably of the globulin fraction. Furthermore, what achieves the above object is a suppressor T cell removal device comprising a container through which a body fluid containing suppressor T cells can flow, and a carrier on which an anti-suppressor T cell antibody contained in the container is immobilized. Further, in the present invention, the carrier is a fibrous material, a tubular material, a granular material, a spherical material, or a film-like material, and the material thereof is activated carbon, a polysaccharide, a protein, or a synthetic resin. Furthermore, antibodies can be obtained by absorbing inactivated serum, which is immunoreactive against antigens with immunosuppressive ability, with red blood cells, and then extracting the γ-globulin fraction from this serum using the 1/3 ammonium sulfate saturation method. It is something. DETAILED DESCRIPTION OF THE INVENTION FIG. 1 shows an apparatus for removing immunosuppressive cells from body fluids, which contains a carrier 2 in a container 1. This container 1 has a blood inlet 3 and a blood outlet 4 formed at both ends, and filters 5 and 5 are provided at the inlets and outlets, respectively. These filters 5,
5 prevents the carrier 2 from flowing out of the container 1. The carrier 2 is a solidified product of a cell membrane antigen of immunosuppressive cells, that is, an antibody that specifically reacts with the cell membrane as an antigen, and is formed of a fibrous material, a tubular material, a granular material, or a spherical material. This carrier 2 is
It is preferable to fill the container to such an extent that body fluids such as blood passing through the container can efficiently contact the antibody. The material of the carrier 2 having these shapes is as follows:
Activated carbon, polysaccharides, proteins, synthetic resins, etc. are suitable, and examples of polysaccharides include cellulose, agarose, fibrin, and collagen. Examples of synthetic resins include polystyrene, polyvinyl chloride, polyvinyl alcohol, polyvinylpyrrolidone, polycarbonate, nylon, silicone, and polyoxymethylene. Note that these materials are not limited to the entire carrier 2, and may be formed only on the surface to which the antibody is attached. The antibody immobilized on carrier 2 is an anti-suppressor T cell antibody when the immunosuppressive cells to be removed are suppressor T cells. This anti-suppressor T cell antibody is obtained by immunizing a given animal with cells that have been confirmed to have immunosuppressive ability as an antigen, separating and inactivating the serum from the post-immunized blood, and then absorbing the serum with red blood cells. This is a γ-globulin fraction extracted by the 1/3 ammonium sulfate saturation method. This antibody can be immobilized on a carrier using a known method using, for example, glutaraldehyde. Therefore, the container 1 containing the carrier 2 is
As shown in the figure, the blood inflow port 3 is connected to the human body 7 or the blood storage device through the drip chamber 6, and the blood outflow port 4 is connected to the human body 7 or the blood storage device through the drip chamber 8. Connected. Although not shown, this device is provided with a mechanism for supplying an anticoagulant such as heparin into the blood to prevent blood from coagulating. Specific Functions and Effects of the Invention In the apparatus for removing immunosuppressive cells in body fluids configured as described above, blood is returned to the body through the container 1 by the operation of the blood pump 9. Inside container 1,
Since a predetermined antibody is immobilized on the carrier 2, it specifically reacts with the cell membrane antigen of immunosuppressive cells and selectively captures these cells. In this case, cells other than immunosuppressive cells are not captured by this antibody and are returned to the body. Furthermore, since immunosuppressive cells are removed by immobilizing antibodies on the carrier 2, no operational problems such as blockage of the channel system or reduction in throughput occur. The effects of the present invention as described above were confirmed by the experiments shown below. First, suppressor T cells used as antigens in this experiment were obtained as follows. 200 ml of blood was collected from a human elbow vein, layered with Fico-Conley specific gravity solution, and heated at 2000γpm for 20 minutes.
After centrifugation for a minute, the intermediate lymphocyte layer is separated and suspended in physiological saline at 2×10 6 cells/ml. This suspension was mixed with 2% neuraminidase-treated sheep red blood cells and centrifuged at 400 x g for 5 minutes.
This is left to stand at 4°C for 1 hour. Here, the lymphocytes are gently suspended, applied again to the Fico-Conrey density solution, and centrifuged at 2000 γpm for 20 minutes.
After hemolyzing sheep red blood cells in the separated rosette-forming cells with a 0.83% ammonium chloride solution, the cells are washed with physiological saline (1000 γpm, 10 minutes, 3 times). The T cells obtained by this procedure are prepared by adding physiological saline to a concentration of 2×10 6 cells/ml. Next, an equal amount of 1% rabbit anti-human IgG-antibody-sensitized chicken red blood cells is mixed therein, and the mixture is allowed to stand at 4°C for 24 hours. This was layered on Ficoll-Conrey density solution, centrifuged at 2000 γpm for 10 minutes to remove the precipitated rosette-forming cells, then chicken red blood cells were hemolyzed with 0.83% ammonium chloride solution, and washed with physiological saline (1000 γpm, 3 times for 10 minutes). In order to examine the immunosuppressive ability of the suppressor T cells obtained by such operations, the following measurements were performed. Lymphocytes obtained from another healthy person were separated into B cells and T cells by Fuico-Conrey gravity centrifugation, and the number of cells was determined to be 2 x 10 5 cells/ml and 8 x 10 5 cells/ml.
Add 20% FCS (fetal bovine serum) to ml.
Prepared with RPMI1640-HEPES and used as a control cell group. In addition, when adding isolated T cells to healthy human lymphocytes, B cells are 2×10 5 cells/ml, T cells are 2×
10 5 cells/ml, and the isolated T cells were prepared in the above medium to a concentration of 8×10 5 cells/ml to form a test cell group. Add 10 μg of PWM (porkweed mitogen) to 1 ml each of control cell group and test cell group,
Culture for 7 days at 37°C in a 5% CO2 incubator. These control and test cell groups were fluorescently stained with rabbit anti-human Ig (IgG + IgA + IgM) serum and washed with MEM medium (1000 γpm, 5 minutes, 3
After that, more than 500 cells were observed under a fluorescence microscope, and cells with specific fluorescence in the cytoplasm were counted as positive, and the immunosuppressive ability was determined from the appearance rate of Ig-bearing cells. As a result, the number of antibody-producing cells (Ig-bearing cells) was 6% in the control cell group, while it was as low as 1.5% in the test cell group, indicating that the isolated T cells had immunosuppressive ability. On the other hand, suppressor T cell antibodies were obtained as follows. Rabbits were immunized twice at 10-day intervals using 1×10 7 lymphocytes with confirmed immunosuppressive ability as an antigen.
Seven days after the final immunization, whole blood was collected, and the separated serum was collected at 56
It was inactivated by treatment at ℃ for 30 minutes. This was absorbed using an equal amount of human AB type red blood cells at 37°C for 1 hour, and then similarly absorbed using human B cells. This rabbit anti-human suppressor T cell serum was subjected to a 1/3 saturation method using ammonium sulfate to obtain a γ-globulin fraction, which was used as a rabbit anti-human suppressor T cell antibody (hereinafter abbreviated as antibody). Next, in order to examine this antibody, the following cytotoxicity test was performed. The aforementioned suppressor T cells and non-suppressor T cells were each prepared at 2500 cells/mm 3 and added to a microtest plate (#3034, Falcon, trade name) in an amount of 1 μ using a microsyringe. Next, add 1μ of the above antibody and incubate at 22°C for 45 minutes. Then add 5μ of rabbit complement and heat at 22°C.
Incubate for 90 minutes. Add 2μ of eosin to this and further add formalin (PH7.0) for staining and fixation. Then, as a result of counting live cells and dead cells under a microscope and calculating the dead cell rate, suppressor T
The cell group had 95% dead cells, while the non-suppressor T cells had 5% dead cells. From the above results, it was confirmed that this antibody specifically reacts with and kills suppressor T cells. In addition, in order to examine the cytotoxicity of this antibody, we tested rabbit anti-human suppressor T using a microtest plate.
A human lymphocyte cytotoxicity test using cell antibodies was conducted. As a result, as shown in Table 1, this antibody
It showed cytotoxicity up to a 2500-fold dilution and was found to have a high titer.
【表】【table】
【表】
次に本発明の実施例につき説明する。
上述した実験例で用いた抗体をグルタールアル
デヒドを用いた公知法によりナイロン粒子からな
る平均粒径250μmの担体に固定した。この担体
を充填率40%で容器に収容し、第2図に示す除去
装置(容量10ml)を組んだ。ついで胃癌患者から
採取した血液30mlを用いてサプレツサーT細胞の
除去試験を行つた。ここで容器は生理食塩水で十
分に洗浄し、発熱性物質、細菌などの有害物質が
残存していないものを用いた。
血液を毎時120mlの流量で容器内に通して循環
させ、これを2時間行なつて実施前後の血液中の
サプレツサーT細胞をダブルロゼツト法で測定し
た。その結果実施前はリンパ球中のサプレツサー
T細胞比率が20%を示したが、実施後では4%の
正常域にまで低下していることが認められた。
また実施前後にPWM刺激による抗体産生細胞
出現率を細胞形質内イムノグロブリン螢光染色に
より測定した。その結果実施前では2.5%と低い
が、実施後では7%と正常域にまで回復したこと
が確認された。
以上の結果から明らかなように本発明によれ
ば、免疫抑制性細胞の細胞膜抗原に特異的に反応
する抗体を利用したので、該細胞を選択的にしか
も顕著に除去でき、免疫系が関与している疾患に
きわめて有意義である。[Table] Next, examples of the present invention will be described. The antibody used in the above-mentioned experimental example was immobilized on a carrier made of nylon particles with an average particle diameter of 250 μm by a known method using glutaraldehyde. This carrier was placed in a container at a filling rate of 40%, and a removal device (capacity 10 ml) as shown in FIG. 2 was assembled. Next, a suppressor T cell removal test was conducted using 30 ml of blood collected from a gastric cancer patient. Here, the container used was one that had been sufficiently washed with physiological saline and had no residual harmful substances such as pyrogens and bacteria. Blood was circulated through the container at a flow rate of 120 ml per hour for 2 hours, and suppressor T cells in the blood before and after the test were measured by the double rosette method. As a result, the proportion of suppressor T cells in lymphocytes was 20% before the experiment, but it was found to have decreased to the normal range of 4% after the experiment. In addition, the appearance rate of antibody-producing cells due to PWM stimulation was measured by cytoplasmic immunoglobulin fluorescence staining before and after the experiment. As a result, it was confirmed that before the implementation, the rate was low at 2.5%, but after the implementation, it returned to 7%, which is within the normal range. As is clear from the above results, according to the present invention, since an antibody that specifically reacts with the cell membrane antigen of immunosuppressive cells is used, the cells can be selectively and significantly removed, and the immune system is not involved. It is of great significance in treating certain diseases.
第1図は本発明の一実施例を示す除去装置の断
面図、第2図は同除去装置を組込んだシステムの
説明図である。
1……容器、2……担体。
FIG. 1 is a sectional view of a removing device showing an embodiment of the present invention, and FIG. 2 is an explanatory diagram of a system incorporating the removing device. 1... Container, 2... Carrier.
Claims (1)
ツサーT細胞抗体を固定した担体に接触させ、該
体液内のサプレツサーT細胞を該担体に補足させ
て除去することを特徴とするサプレツサーT細胞
除去方法。 2 前記抗サプレツサーT細胞抗体は、免疫抑制
能をもつ抗原に対して免疫反応性を有する非動化
した血清を赤血球で吸収操作した後この血清から
1/3硫安飽和法にて分離したγ−グロブリン分画
のものである特許請求の範囲第1項に記載のサプ
レツサーT細胞除去方法。 3 サプレツサーT細胞を含む体液が流通可能な
容器と、該容器内に収容された抗サプレツサーT
細胞抗体を固定した担体とからなることを特徴と
するサプレツサーT細胞除去装置。 4 前記担体が繊維状物、管状物、顆粒状物、球
状物又は膜状物である特許請求の範囲第3項に記
載のサプレツサーT細胞除去装置。 5 前記担体が、活性炭、多糖体、蛋白質又は合
成樹脂である特許請求の範囲第3項に記載のサプ
レツサーT細胞除去装置。 6 前記抗サプレツサーT細胞抗体は、免疫抑制
能をもつ抗原に対して免疫反応性を有する非動化
した血清を赤血球で吸収操作した後この血清から
1/3硫安飽和法にて分離したγ−グロブリン分画
のものである特許請求の範囲第3項ないし第5項
のいずれかに記載のサプレツサーT細胞除去装
置。[Scope of Claims] 1. A suppressor characterized in that a body fluid containing suppressor T cells is brought into contact with a carrier on which an anti-suppressor T cell antibody is immobilized, and the suppressor T cells in the body fluid are captured by the carrier and removed. T cell removal method. 2. The anti-suppressor T cell antibody is obtained from immobilized serum that is immunoreactive with immunosuppressive antigens after absorption with red blood cells.
The suppressor T cell removal method according to claim 1, which is a γ-globulin fraction separated by a 1/3 ammonium sulfate saturation method. 3 A container through which body fluid containing suppressor T cells can flow, and an anti-suppressor T cell housed in the container.
A suppressor T cell removal device comprising a carrier on which a cell antibody is immobilized. 4. The suppressor T cell removal device according to claim 3, wherein the carrier is a fibrous material, a tubular material, a granular material, a spherical material, or a membranous material. 5. The suppressor T cell removal device according to claim 3, wherein the carrier is activated carbon, polysaccharide, protein, or synthetic resin. 6. The anti-suppressor T cell antibody is obtained from immobilized serum that is immunoreactive with immunosuppressive antigens after absorption with red blood cells.
The suppressor T cell removal device according to any one of claims 3 to 5, which is a γ-globulin fraction separated by a 1/3 ammonium sulfate saturation method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3521780A JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3521780A JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP15922986A Division JPS62123131A (en) | 1986-07-07 | 1986-07-07 | Anti-suppressor t cell antibody and production thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56130160A JPS56130160A (en) | 1981-10-12 |
JPS6260106B2 true JPS6260106B2 (en) | 1987-12-15 |
Family
ID=12435671
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3521780A Granted JPS56130160A (en) | 1980-03-19 | 1980-03-19 | Device for removing immunity inhibiting cell in body fluid |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS56130160A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8637084B2 (en) * | 2009-07-14 | 2014-01-28 | Asahi Kasei Medical Co., Ltd. | Treatment method for epithelial cancerous organism |
US9127250B2 (en) | 2011-03-29 | 2015-09-08 | Shiga University Of Medical Science | Immunosuppressive cell-capturing material and immunosuppressive cell-capturing column |
JP5922373B2 (en) * | 2011-10-31 | 2016-05-24 | 日機装株式会社 | Method and apparatus for manufacturing blood adsorber |
US20200215253A1 (en) * | 2017-09-08 | 2020-07-09 | Toray Industries, Inc. | Immunosuppressive leukocyte adsorption material and adsorption column |
WO2019073992A1 (en) * | 2017-10-11 | 2019-04-18 | 国立大学法人京都大学 | Antibody-modified filter |
-
1980
- 1980-03-19 JP JP3521780A patent/JPS56130160A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS56130160A (en) | 1981-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0276342B1 (en) | Method for treating plasma and products thereof | |
US5122112A (en) | Antigen-specific removal of circulating immune complexes | |
US5147289A (en) | Non-specific immune system enhancement | |
US4464165A (en) | Material and method for removing immunoglobulins from whole blood | |
Augustin et al. | Human reagins to grass pollens and moulds: their purification and physico-chemical characterization | |
US4865841A (en) | Methods and compositions for transient elimination of humoral immune antibodies | |
US4512763A (en) | Method and apparatus for selective removal of constituents of blood | |
EP0421380B1 (en) | Tumor-lysing cell inducer, method for inducing tumor-lysing cell and device for inducing tumor-lysing cell | |
JPS6260106B2 (en) | ||
Bentwich et al. | Antigenic changes on the surface of lymphocytes from patients with chronic lymphocytic leukemia | |
Drew et al. | Autoimmune cytotoxic granulocyte antibodies in normal persons and various diseases | |
EP0272792B1 (en) | Antigen-specific removal of circulating immune complexes | |
US4409330A (en) | Material and method for removing immunoglobulins from whole blood | |
Miller et al. | Thymic dysplasia (“Swiss agammaglobulinemia”): II. Morphologic and functional observations | |
Edelson | Round cells of the epidermis: clues from studies on neoplastic lymphocytes of cutaneous T cell lymphoma | |
Ray et al. | Effect of frequency of plasma adsorption over protein A-containing Staphylococcus aureus on regression of rat mammary adenocarcinomas: Modification of antitumor immune response and tumor histopathology | |
Hornung et al. | The Use of Human F (ab′) 2 Fragments as Blocking Agents in the Mixed Lymphocyte Reaction | |
Janković et al. | Passive transfer of experimental allergic thyroiditis, delayed hypersensitivity to thyroglobulin and anti-thyroglobulin antibody formation in inbred Lewis rats | |
JPS62123131A (en) | Anti-suppressor t cell antibody and production thereof | |
Sjöberg et al. | Conditions for induction of specific and polyclonal antibody production by Cowan 1 bacteria and by pokeweed mitogen | |
EA035338B1 (en) | Composition of hematopoietic stem cells with reduced inflammatory activity, production and use thereof | |
Amemiya et al. | The nature of antiplatelet activity in antilymphoblast ALG: with special reference to crossreacting antibody, immunochemical characterization, and Coombs' positive thrombocytopenia in ALG-treated renal recipients | |
KHOSRAVI et al. | Relationship of melanoma-Associated antigens to histocompatibility antigen and β-2 microglobulin in material spontaneously shed by cultured human melanoma cells | |
Sundharagiati et al. | A CLINICAL AND EXPERIMENTAL STUDY OF THE ERYTHRO-CYTE ULTRASTRUCTURE MEMBRANE WITH THE ELECTRON MICROSCOPE | |
JPS59116224A (en) | Immunological reaction controlling composition and manufacture |